ClinicalTrials.Veeva

Menu

Growth Hormone Resistance of Beta-cells (GHRB-A)

University of Missouri (MU) logo

University of Missouri (MU)

Status

Enrolling

Conditions

Gestational Diabetes
Healthy
Obesity

Study type

Observational

Funder types

Other

Identifiers

NCT06571487
2111127-A

Details and patient eligibility

About

The purpose of the research study is to better understand how beta-cells (cells in the pancreas that make insulin and help regulate blood sugar) respond to growth hormone in people with a personal history of gestational diabetes (high blood sugar in pregnancy) at the University of Missouri. The aim of the study is to advance understanding of how growth hormone affects beta-cells and risk factors for developing gestational diabetes and type 2 diabetes.

Enrollment

30 estimated patients

Sex

Female

Ages

18 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Singleton, full term pregnancy within the past 5 years
  • Hemoglobin HbA1c ≤5.6% and fasting blood glucose <100 mg/dl
  • Body mass index ≥30.0 kg/m2 and <45.0 kg/m2, because the majority of women with GDM have overweight/obesity

Group specific inclusion criteria:

  • Gestational Diabetes Group: History of gestational diabetes in the most recent pregnancy
  • Control Group: no history of gestational diabetes

Exclusion criteria

  • Pregnant, planning to become pregnant during the study, or breastfeeding
  • Current diagnosis or history of type 1 or type 2 diabetes
  • Use of medications that can impact the study outcomes (e.g., GLP-1 receptor agonists)
  • History of bariatric surgery
  • Known hypothyroidism or use of thyroid medications
  • History of intracranial hypertension, including papilledema, or a condition that increases the risk of developing intracranial hypertension, such as Turner Syndrome, Prader-Willi Syndrome, or renal impairment
  • Current cancer or cancer that has been in remission less than 5 years
  • First degree relative with diabetes diagnosis
  • Evidence of significant anemia or significant end organ dysfunction (e.g., liver, kidney, heart disease)
  • Alcohol use disorder, use of controlled substances, or smoking >2 cigarettes per day
  • Greater than 3% weight loss within three months of screening or engaged in regular (≥3 days per week), continuous moderate- or high-intensity exercise of ≥30 min duration
  • Mentally disabled persons, prisoners, and persons with inability to grant voluntary informed consent

Trial design

30 participants in 2 patient groups

Women with a history of gestational diabetes mellitus
Women without a history of gestational diabetes mellitus

Trial contacts and locations

1

Loading...

Central trial contact

Amanda Heider; Vasavi Shabrish, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems